Sinopharm Group Co Ltd banner

Sinopharm Group Co Ltd
XMUN:X2S

Watchlist Manager
Sinopharm Group Co Ltd Logo
Sinopharm Group Co Ltd
XMUN:X2S
Watchlist
Price: 1.753 EUR 0.46% Market Closed
Market Cap: €2.4B

Wall St Price Targets

X2S Price Targets Summary
Sinopharm Group Co Ltd

Wall Street analysts forecast X2S stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for X2S is 2.518 EUR with a low forecast of 1.874 EUR and a high forecast of 3.091 EUR.

Lowest Forecast
Price Target
1.874 EUR
7% Upside
Average Forecast
Price Target
2.518 EUR
44% Upside
Highest Forecast
Price Target
3.091 EUR
76% Upside
Sinopharm Group Co Ltd Competitors:
Price Targets
CAH
Cardinal Health Inc
8% Upside

Revenue
Forecast

13% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
13% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 14 years, the compound annual growth rate for Revenue has been 13%. The projected CAGR for the next 3 years is 5%.

Gross Profit
Forecast

12% / Year
Past Growth
9% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
12% / Year
Past Growth
9% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 14 years, the compound annual growth rate for Gross Profit has been 12%. The projected CAGR for the next 3 years is 9%.

Operating Income
Forecast

11% / Year
Past Growth
26% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat
11% / Year
Past Growth
26% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat

Over the last 14 years, the compound annual growth rate for Operating Income has been 11%. The projected CAGR for the next 3 years is 26%.

Pre-Tax Income
Forecast

12% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss
12% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss

Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 12%. The projected CAGR for the next 3 years is 10%.

Net Income
Forecast

11% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
11% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 14 years, the compound annual growth rate for Net Income has been 11%. The projected CAGR for the next 3 years is 10%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is X2S's stock price target?
Price Target
2.518 EUR

According to Wall Street analysts, the average 1-year price target for X2S is 2.518 EUR with a low forecast of 1.874 EUR and a high forecast of 3.091 EUR.

What is the Revenue forecast for Sinopharm Group Co Ltd?
Projected CAGR
5%

Over the last 14 years, the compound annual growth rate for Revenue has been 13%. The projected CAGR for the next 3 years is 5%.

What is the Gross Profit forecast for Sinopharm Group Co Ltd?
Projected CAGR
9%

Over the last 14 years, the compound annual growth rate for Gross Profit has been 12%. The projected CAGR for the next 3 years is 9%.

What is the Operating Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
26%

Over the last 14 years, the compound annual growth rate for Operating Income has been 11%. The projected CAGR for the next 3 years is 26%.

What is the Pre-Tax Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
10%

Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 12%. The projected CAGR for the next 3 years is 10%.

What is the Net Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
10%

Over the last 14 years, the compound annual growth rate for Net Income has been 11%. The projected CAGR for the next 3 years is 10%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett